Trial · NCT07899775
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
NCT07899775, Not yet recruiting, Hainan General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC. Trials, record NCT07899775. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899775
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
- NCT number
- NCT07899775
- Status
- Not yet recruiting
- Enrollment
- 103 participants, estimated
- Lead sponsor
- Hainan General Hospital
- Conditions
- Stomach Neoplasms, Gastric Cancer (Diagnosis), Gastric Adenocarcinoma
- Interventions
- Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy | Up to 2 weeks | The primary outcome is the station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy, assessed by station-by-station pathologic examination of gastrectomy specimens. Each dissected nodal station (No. 1-No. 16, as applicable) is evaluated separately. For each station, the positivity rate is defined as the number of evaluable participants with at least one pathologically confirmed positive lymph node at that station divided by the number of evaluable participants in whom that station was pathologically assessed. A positive node is defined as a lymph node containing viable tumor cells on hematoxylin and eosin staining. Pathologic assessment is performed blinded to preoperative imaging, iRECIST response, and clinical treatment information. The outcome is assessed at postoperative pathology after D2 gastrectomy. |
| Secondary | Degree of Peritumoral Edema and Fibrosis | Perioperative | To evaluate the extent of peritumoral tissue edema, fibrosis, and dense adhesions during the surgical procedure. The primary surgeon will objectively assess these local microenvironment changes using a semi-quantitative grading scale ranging from Grade 0 (normal anatomical planes, no obvious adhesions) to Grade 3 ("frozen" extremely dense adhesions, anatomical planes completely disappeared). The study will also analyze the correlation between the degree of edema/fibrosis and surgical complexity metrics, such as total surgical time and intraoperative blood loss. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899775
GET https://conductscience.org/api/trials/v1/NCT07899775/registered